Evidence map›Paper›PMID 37333090›Full record

ArticlebioRxiv : the preprint server for biology2023

The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics.

Sook Wah Yee, Christian Macdonald, Darko Mitrovic, Xujia Zhou, Megan L Koleske, Jia Yang, Dina Buitrago Silva, Patrick Rockefeller Grimes, Donovan Trinidad, Swati S More and 5 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Sook Wah YeeDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, United States.
Christian MacdonaldDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, United States.
Darko MitrovicScience for Life Laboratory, Department of Applied Physics, KTH Royal Institute of Technology, 12121 Solna, Sweden.
Xujia ZhouDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, United States.
Megan L KoleskeDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, United States.
Jia YangDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, United States.
Dina Buitrago SilvaDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, United States.
Patrick Rockefeller GrimesDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, United States.
Donovan TrinidadDepartment of Medicine, Division of Infectious Disease, University of California, San Francisco, United States.
Swati S MoreDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, United States.
Linda KachuriEpidemiology and Population Health, Stanford University, California, United States.
John S WitteEpidemiology and Population Health, Stanford University, California, United States.
Lucie DelemotteScience for Life Laboratory, Department of Applied Physics, KTH Royal Institute of Technology, 12121 Solna, Sweden.
Kathleen M GiacominiDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, United States.
Willow Coyote-MaestasDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, United States.
University of California, San Francisco · USScience for Life Laboratory · SEUniversity of Minnesota · US

Funding

Equipment Supplement for Discovery of Pharmacogenomic Biomarkers for OATP1B1 and OATP1B3R01GM117163 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FLOREZ, JOSE CARLOS, HEDDERSON, MONIQUE MARIE · 2015 to 2023
$5.5M
Equipment Supplement NOT-GM-24-021R01GM139875 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GIACOMINI, KATHLEEN M · 2021 to 2024
$1.9M
Illumina NovaSeq 6000 Sequencing SystemS10OD028511 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOW, ERIC D · 2020 to 2020
$583k
Connecting structure and fitness landscapes to overcome antibiotic resistanceF32GM152977 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MACDONALD, CHRISTIAN BERNARD · 2023 to 2024
$146k
Understanding the mechanisms of ESX secretion systems in mycobacteriaF31AI157438 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TRINIDAD, DONOVAN DAVID · 2021 to 2023
$127k
NIAID NIH HHS F31 AI157438NIGMS NIH HHS F32 GM152977NIGMS NIH HHS R01 GM117163NIGMS NIH HHS R01 GM139875NIH HHS S10 OD028511
6 · The paper itself

Abstract

Membrane transporters play a fundamental role in the tissue distribution of endogenous compounds and xenobiotics and are major determinants of efficacy and side effects profiles. Polymorphisms within these drug transporters result in inter-individual variation in drug response, with some patients not responding to the recommended dosage of drug whereas others experience catastrophic side effects. For example, variants within the major hepatic Human organic cation transporter OCT1 (SLC22A1) can change endogenous organic cations and many prescription drug levels. To understand how variants mechanistically impact drug uptake, we systematically study how all known and possible single missense and single amino acid deletion variants impact expression and substrate uptake of OCT1. We find that human variants primarily disrupt function via folding rather than substrate uptake. Our study revealed that the major determinants of folding reside in the first 300 amino acids, including the first 6 transmembrane domains and the extracellular domain (ECD) with a stabilizing and highly conserved stabilizing helical motif making key interactions between the ECD and transmembrane domains. Using the functional data combined with computational approaches, we determine and validate a structure-function model of OCT1s conformational ensemble without experimental structures. Using this model and molecular dynamic simulations of key mutants, we determine biophysical mechanisms for how specific human variants alter transport phenotypes. We identify differences in frequencies of reduced function alleles across populations with East Asians vs European populations having the lowest and highest frequency of reduced function variants, respectively. Mining human population databases reveals that reduced function alleles of OCT1 identified in this study associate significantly with high LDL cholesterol levels. Our general approach broadly applied could transform the landscape of precision medicine by producing a mechanistic basis for understanding the effects of human mutations on disease and drug response.

Identifiers

PMID37333090
PMCPMC10274788
OpenAlexW4380052734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.